Table 4. Univariate and Multivariate Cox Proportional Hazards Regression Analysis of Overall Survival for All 485 Patients.
| Characteristic | Univariable | Multivariable | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Female sex | 1.08 (0.86-1.35) | .50 | NA | NA |
| BMI | 1.01 (0.98-1.02) | .60 | NA | NA |
| Age ≥75 y | 0.98 (0.69-1.37) | .90 | NA | NA |
| ECOG PS ≥2 | 1.37 (0.95-1.97) | .09 | 1.47 (1.01-2.13) | .04 |
| First-line chemotherapy regimen | ||||
| FOLFIRINOX | 1 [Reference] | NA | NA | NA |
| GA | 0.91 (0.72-1.15) | .50 | 1.14 (0.89-1.44) | .30 |
| Baseline CA 19-9 level | 1.01 (1.00-1.01) | .001 | 1.01 (1.00-1.01) | .001 |
| Tumor site | NA | NA | ||
| Body or tail | 1 [Reference] | NA | NA | |
| Head or neck | 0.96 (0.74-1.25) | .50 | NA | |
| Baseline radiographic stage | NA | NA | ||
| Resectable | 0.70 (0.54-0.91) | .001 | 0.60 (0.45-0.80) | .001 |
| Borderline resectable | 0.86 (0.65-1.15) | .30 | 0.79 (0.59-1.06) | .10 |
| Locally advanced | 1 [Reference] | NA | NA | NA |
| No. of chemotherapy cycles | 0.95 (0.91-0.99) | .03 | 0.92 (0.88-0.96) | .001 |
Abbreviations: BMI, body mass index; CA 19-9, cancer antigen 19-9; ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFIRINOX, fluorouracil, leucovorin, irinotecan, and oxaliplatin; GA, gemcitabine plus nanoparticle albumin-bound paclitaxel; HR, hazard ratio; NA, not applicable.